Could a 3-Week radiation blast tame HPV throat cancer?

NCT ID NCT04580446

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a shorter, more intense radiation schedule (completed in 3 weeks instead of the usual 6) combined with chemotherapy for people with HPV-related throat cancer. The goal was to find the safest dose that still controls the cancer. Only 24 patients took part, and the main focus was on side effects, not yet on cure rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
hypofractionated radiation therapy with weekly cisplatin
What this could lead to
If successful, this could lead to a shorter, more convenient radiation treatment for HPV-related throat cancer with fewer side effects.
What could go wrong
This is a very early phase 1 trial with only 24 people, so safety and effectiveness are not yet proven. The shorter radiation schedule might not control the cancer as well or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.